183 related articles for article (PubMed ID: 36906459)
21. Somatic double-hit in MTOR and RPS6 in hemimegalencephaly with intractable epilepsy.
Pelorosso C; Watrin F; Conti V; Buhler E; Gelot A; Yang X; Mei D; McEvoy-Venneri J; Manent JB; Cetica V; Ball LL; Buccoliero AM; Vinck A; Barba C; Gleeson JG; Guerrini R; Represa A
Hum Mol Genet; 2019 Nov; 28(22):3755-3765. PubMed ID: 31411685
[TBL] [Abstract][Full Text] [Related]
22. mTOR pathway: Insights into an established pathway for brain mosaicism in epilepsy.
Gerasimenko A; Baldassari S; Baulac S
Neurobiol Dis; 2023 Jun; 182():106144. PubMed ID: 37149062
[TBL] [Abstract][Full Text] [Related]
23. mTOR dysregulation and tuberous sclerosis-related epilepsy.
Curatolo P; Moavero R; van Scheppingen J; Aronica E
Expert Rev Neurother; 2018 Mar; 18(3):185-201. PubMed ID: 29338461
[TBL] [Abstract][Full Text] [Related]
24. Focal cortical dysplasia pathology: diagnostic difficulty, classification, and utility for pathogenesis.
Kapar O; Gurkan ZM; Dolgun M; Sencer A; Gürses C; Bilgic B
Neurosurg Focus; 2022 Oct; 53(4):E6. PubMed ID: 36183176
[TBL] [Abstract][Full Text] [Related]
25. Mammalian target of rapamycin (mTOR) activation in focal cortical dysplasia and related focal cortical malformations.
Wong M
Exp Neurol; 2013 Jun; 244():22-6. PubMed ID: 22015915
[TBL] [Abstract][Full Text] [Related]
26. mTOR Inhibitors as a New Therapeutic Strategy in Treatment Resistant Epilepsy in Hemimegalencephaly: A Case Report.
Xu Q; Uliel-Sibony S; Dunham C; Sarnat H; Flores-Sarnat L; Brunga L; Davidson S; Lo W; Shlien A; Connolly M; Boelman C; Datta A
J Child Neurol; 2019 Mar; 34(3):132-138. PubMed ID: 30514132
[TBL] [Abstract][Full Text] [Related]
27. mTOR-dependent abnormalities in autophagy characterize human malformations of cortical development: evidence from focal cortical dysplasia and tuberous sclerosis.
Yasin SA; Ali AM; Tata M; Picker SR; Anderson GW; Latimer-Bowman E; Nicholson SL; Harkness W; Cross JH; Paine SM; Jacques TS
Acta Neuropathol; 2013 Aug; 126(2):207-18. PubMed ID: 23728790
[TBL] [Abstract][Full Text] [Related]
28. Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies.
Wong M
Epilepsia; 2010 Jan; 51(1):27-36. PubMed ID: 19817806
[TBL] [Abstract][Full Text] [Related]
29. Is mTOR inhibition a systemic treatment for tuberous sclerosis?
Moavero R; Coniglio A; Garaci F; Curatolo P
Ital J Pediatr; 2013 Sep; 39():57. PubMed ID: 24044547
[TBL] [Abstract][Full Text] [Related]
30. Profiling PI3K-AKT-MTOR variants in focal brain malformations reveals new insights for diagnostic care.
Pirozzi F; Berkseth M; Shear R; Gonzalez L; Timms AE; Sulc J; Pao E; Oyama N; Forzano F; Conti V; Guerrini R; Doherty ES; Saitta SC; Lockwood CM; Pritchard CC; Dobyns WB; Novotny E; Wright JNN; Saneto RP; Friedman S; Hauptman J; Ojemann J; Kapur RP; Mirzaa GM
Brain; 2022 Apr; 145(3):925-938. PubMed ID: 35355055
[TBL] [Abstract][Full Text] [Related]
31. Review: Mechanistic target of rapamycin (mTOR) pathway, focal cortical dysplasia and epilepsy.
Marsan E; Baulac S
Neuropathol Appl Neurobiol; 2018 Feb; 44(1):6-17. PubMed ID: 29359340
[TBL] [Abstract][Full Text] [Related]
32. Cortical Dysplasia and the mTOR Pathway: How the Study of Human Brain Tissue Has Led to Insights into Epileptogenesis.
Lee WS; Baldassari S; Stephenson SEM; Lockhart PJ; Baulac S; Leventer RJ
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163267
[TBL] [Abstract][Full Text] [Related]
33. mTOR Inhibitors in Children: Current Indications and Future Directions in Neurology.
Jeong A; Wong M
Curr Neurol Neurosci Rep; 2016 Dec; 16(12):102. PubMed ID: 27815691
[TBL] [Abstract][Full Text] [Related]
34. Somatic variants in diverse genes leads to a spectrum of focal cortical malformations.
Lai D; Gade M; Yang E; Koh HY; Lu J; Walley NM; Buckley AF; Sands TT; Akman CI; Mikati MA; McKhann GM; Goldman JE; Canoll P; Alexander AL; Park KL; Von Allmen GK; Rodziyevska O; Bhattacharjee MB; Lidov HGW; Vogel H; Grant GA; Porter BE; Poduri AH; Crino PB; Heinzen EL
Brain; 2022 Aug; 145(8):2704-2720. PubMed ID: 35441233
[TBL] [Abstract][Full Text] [Related]
35. Focal malformations of cortical development: new vistas for molecular pathogenesis.
Lim KC; Crino PB
Neuroscience; 2013 Nov; 252():262-76. PubMed ID: 23892008
[TBL] [Abstract][Full Text] [Related]
36. Activation of extracellular regulated kinase and mechanistic target of rapamycin pathway in focal cortical dysplasia.
Patil VV; Guzman M; Carter AN; Rathore G; Yoshor D; Curry D; Wilfong A; Agadi S; Swann JW; Adesina AM; Bhattacharjee MB; Anderson AE
Neuropathology; 2016 Apr; 36(2):146-56. PubMed ID: 26381727
[TBL] [Abstract][Full Text] [Related]
37. Advances in the mTOR signaling pathway and its inhibitor rapamycin in epilepsy.
Zhao W; Xie C; Zhang X; Liu J; Liu J; Xia Z
Brain Behav; 2023 Jun; 13(6):e2995. PubMed ID: 37221133
[TBL] [Abstract][Full Text] [Related]
38. Hemimegalencephaly and tuberous sclerosis complex: A rare yet challenging association.
Sidira C; Vargiami E; Dragoumi P; Zafeiriou DI
Eur J Paediatr Neurol; 2021 Jan; 30():58-65. PubMed ID: 33387903
[TBL] [Abstract][Full Text] [Related]
39. mTOR inhibitors as a new therapeutic option for epilepsy.
Curatolo P; Moavero R
Expert Rev Neurother; 2013 Jun; 13(6):627-38. PubMed ID: 23739000
[TBL] [Abstract][Full Text] [Related]
40. The Putative Role of mTOR Inhibitors in Non-tuberous Sclerosis Complex-Related Epilepsy.
Goldstein HE; Hauptman JS
Front Neurol; 2021; 12():639319. PubMed ID: 33643212
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
